{"id":"https://openalex.org/W4378549583","doi":"https://doi.org/10.1016/j.neuropharm.2023.109610","title":"Psychedelics: Threshold of a Therapeutic Revolution","display_name":"Psychedelics: Threshold of a Therapeutic Revolution","publication_year":2023,"publication_date":"2023-05-27","ids":{"openalex":"https://openalex.org/W4378549583","doi":"https://doi.org/10.1016/j.neuropharm.2023.109610","pmid":"https://pubmed.ncbi.nlm.nih.gov/37247807"},"language":"en","primary_location":{"id":"doi:10.1016/j.neuropharm.2023.109610","doi":"https://doi.org/10.1016/j.neuropharm.2023.109610","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.neuropharm.2023.109610","pdf_url":null,"source":{"id":"https://openalex.org/S160566677","display_name":"Neuropharmacology","issn_l":"0028-3908","issn":["0028-3908","1873-7064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"journal-article"},"volume":null,"type":"editorial","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.neuropharm.2023.109610","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037798281","display_name":"David J. Heal","orcid":"https://orcid.org/0000-0002-6128-9632","observed_orcids":["https://orcid.org/0000-0002-6128-9632"]},"institutions":[{"id":"https://openalex.org/I4210120610","display_name":"Biomedical Translation Research Center","ror":"https://ror.org/01whq1k34","country_code":"TW","type":"facility","lineage":["https://openalex.org/I4210120610","https://openalex.org/I84653119"]},{"id":"https://openalex.org/I4210136357","display_name":"Dexcel Pharma (United Kingdom)","ror":"https://ror.org/03zh2yp19","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210136357"]},{"id":"https://openalex.org/I4405267125","display_name":"Xiamen Innovax Biotech Co., Ltd. (China)","ror":"https://ror.org/01a51nj96","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267125"]},{"id":"https://openalex.org/I4405267148","display_name":"BioLineRx Ltd. (Israel)","ror":"https://ror.org/01d7sbt11","country_code":"IL","type":"company","lineage":["https://openalex.org/I4405267148"]},{"id":"https://openalex.org/I51601045","display_name":"University of Bath","ror":"https://ror.org/002h8g185","country_code":"GB","type":"education","lineage":["https://openalex.org/I51601045"]}],"countries":["CN","GB","IL","TW"],"is_corresponding":true,"raw_author_name":"D.J. Heal","raw_affiliation_strings":["DevelRx Ltd, BioCity, Nottingham, NG1 1GF, UK; Department of Life Sciences, University of Bath, Bath, BA2 7AY, UK. Electronic address: david.heal@develrx.com","Department of Life Sciences, University of Bath, Bath BA2 7AY, UK","DevelRx Ltd, BioCity, Nottingham NG1 1GF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DevelRx Ltd, BioCity, Nottingham, NG1 1GF, UK; Department of Life Sciences, University of Bath, Bath, BA2 7AY, UK. Electronic address: david.heal@develrx.com","institution_ids":["https://openalex.org/I51601045"]},{"raw_affiliation_string":"Department of Life Sciences, University of Bath, Bath BA2 7AY, UK","institution_ids":["https://openalex.org/I51601045"]},{"raw_affiliation_string":"DevelRx Ltd, BioCity, Nottingham NG1 1GF, UK","institution_ids":["https://openalex.org/I4210120610","https://openalex.org/I4210136357","https://openalex.org/I4405267125","https://openalex.org/I4405267148"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057634008","display_name":"Sharon L. Smith","orcid":"https://orcid.org/0000-0002-4801-8475","observed_orcids":["https://orcid.org/0000-0002-4801-8475"]},"institutions":[{"id":"https://openalex.org/I4210120610","display_name":"Biomedical Translation Research Center","ror":"https://ror.org/01whq1k34","country_code":"TW","type":"facility","lineage":["https://openalex.org/I4210120610","https://openalex.org/I84653119"]},{"id":"https://openalex.org/I4210136357","display_name":"Dexcel Pharma (United Kingdom)","ror":"https://ror.org/03zh2yp19","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210136357"]},{"id":"https://openalex.org/I4405267125","display_name":"Xiamen Innovax Biotech Co., Ltd. (China)","ror":"https://ror.org/01a51nj96","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267125"]},{"id":"https://openalex.org/I4405267148","display_name":"BioLineRx Ltd. (Israel)","ror":"https://ror.org/01d7sbt11","country_code":"IL","type":"company","lineage":["https://openalex.org/I4405267148"]}],"countries":["CN","GB","IL","TW"],"is_corresponding":true,"raw_author_name":"S.L. Smith","raw_affiliation_strings":["DevelRx Ltd, BioCity, Nottingham, NG1 1GF, UK. Electronic address: sharon.smith@develrx.com","DevelRx Ltd, BioCity, Nottingham NG1 1GF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DevelRx Ltd, BioCity, Nottingham, NG1 1GF, UK. Electronic address: sharon.smith@develrx.com","institution_ids":[]},{"raw_affiliation_string":"DevelRx Ltd, BioCity, Nottingham NG1 1GF, UK","institution_ids":["https://openalex.org/I4210120610","https://openalex.org/I4210136357","https://openalex.org/I4405267125","https://openalex.org/I4405267148"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002348397","display_name":"Sean J. Belouin","orcid":"https://orcid.org/0000-0002-6231-8992","observed_orcids":["https://orcid.org/0000-0002-6231-8992"]},"institutions":[{"id":"https://openalex.org/I1336377119","display_name":"Substance Abuse and Mental Health Services Administration","ror":"https://ror.org/03t3qg659","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1336377119"]},{"id":"https://openalex.org/I35344726","display_name":"United States Public Health Service","ror":"https://ror.org/05xf94514","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I35344726"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"S.J. Belouin","raw_affiliation_strings":["United States Public Health Service (USPHS), Germantown, MD, USA; Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD, USA; NIH Clinical Research Center, Pain and Palliative Care, Bethesda, MD, USA. Electronic address: sjbelouin@gmail.com","NIH Clinical Research Center, Pain and Palliative Care, Bethesda, MD, USA","Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD, USA","United States Public Health Service (USPHS), Germantown, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"United States Public Health Service (USPHS), Germantown, MD, USA; Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD, USA; NIH Clinical Research Center, Pain and Palliative Care, Bethesda, MD, USA. Electronic address: sjbelouin@gmail.com","institution_ids":["https://openalex.org/I1336377119","https://openalex.org/I35344726"]},{"raw_affiliation_string":"NIH Clinical Research Center, Pain and Palliative Care, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210155647"]},{"raw_affiliation_string":"Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD, USA","institution_ids":["https://openalex.org/I1336377119"]},{"raw_affiliation_string":"United States Public Health Service (USPHS), Germantown, MD, USA","institution_ids":["https://openalex.org/I35344726"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034406366","display_name":"Jack E. Henningfield","orcid":"https://orcid.org/0000-0001-8387-0041","observed_orcids":["https://orcid.org/0000-0001-8387-0041"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I2799853436","display_name":"Johns Hopkins Medicine","ror":"https://ror.org/037zgn354","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436"]},{"id":"https://openalex.org/I4387152626","display_name":"Pinney Associates (United States)","ror":"https://ror.org/04vh4pp56","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152626"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"J.E. Henningfield","raw_affiliation_strings":["Pinney Associates, 4800 Montgomery Ln Suite 400, Bethesda, MD, 20814, USA; Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA. Electronic address: jhenning@pinneyassociates.com","Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA","Pinney Associates, 4800 Montgomery Ln Suite 400, Bethesda, MD 20814, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pinney Associates, 4800 Montgomery Ln Suite 400, Bethesda, MD, 20814, USA; Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA. Electronic address: jhenning@pinneyassociates.com","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I2799853436"]},{"raw_affiliation_string":"Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I2799853436"]},{"raw_affiliation_string":"Pinney Associates, 4800 Montgomery Ln Suite 400, Bethesda, MD 20814, USA","institution_ids":["https://openalex.org/I4387152626"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5002348397","https://openalex.org/A5034406366","https://openalex.org/A5037798281","https://openalex.org/A5057634008"],"corresponding_institution_ids":["https://openalex.org/I1336377119","https://openalex.org/I145311948","https://openalex.org/I2799853436","https://openalex.org/I35344726","https://openalex.org/I4210120610","https://openalex.org/I4210136357","https://openalex.org/I4210155647","https://openalex.org/I4387152626","https://openalex.org/I4405267125","https://openalex.org/I4405267148","https://openalex.org/I51601045"],"apc_list":{"value":4050,"currency":"USD","value_usd":4050},"apc_paid":{"value":4050,"currency":"USD","value_usd":4050},"fwci":null,"has_fulltext":false,"cited_by_count":60,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"236","issue":null,"first_page":"109610","last_page":"109610"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12553","display_name":"Psychedelics and Drug Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12553","display_name":"Psychedelics and Drug Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10509","display_name":"Religion, Spirituality, and Psychology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3306","display_name":"Health"},"field":{"id":"https://openalex.org/fields/33","display_name":"Social Sciences"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/psychedelics","display_name":"psychedelics","score":0.9990000128746033},{"id":"https://openalex.org/keywords/psilocybin","display_name":"psilocybin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mdma","display_name":"MDMA","score":0.9800000190734863},{"id":"https://openalex.org/keywords/treatment-resistant-depression","display_name":"treatment-resistant depression","score":0.8489999771118164},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9950000047683716},{"id":"https://openalex.org/keywords/posttraumatic-stress-disorder","display_name":"post-traumatic stress disorder","score":0.9789999723434448},{"id":"https://openalex.org/keywords/breakthrough-therapy-designation","display_name":"breakthrough therapy designation","score":0.9150000214576721},{"id":"https://openalex.org/keywords/psychedelic-therapy","display_name":"psychedelic therapy","score":0.4749999940395355},{"id":"https://openalex.org/keywords/clinical-trials","display_name":"clinical trials","score":0.5889999866485596},{"id":"https://openalex.org/keywords/substance-use-disorders","display_name":"substance use disorders","score":0.6890000104904175},{"id":"https://openalex.org/keywords/chronic-pain","display_name":"chronic pain","score":0.7900000214576721},{"id":"https://openalex.org/keywords/depression-in-cancer-patients","display_name":"cancer-related depression","score":0.7289999723434448},{"id":"https://openalex.org/keywords/regulatory-policy","display_name":"regulatory policy","score":0.5080000162124634},{"id":"https://openalex.org/keywords/fda-drug-approval","display_name":"FDA drug approval","score":0.6359999775886536}],"concepts":[{"id":"https://openalex.org/C2776502132","wikidata":"https://www.wikidata.org/wiki/Q208118","display_name":"Psilocybin","level":3,"score":0.9227741360664368},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5083937048912048},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4561036229133606},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4353374242782593},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.4159146249294281},{"id":"https://openalex.org/C124315065","wikidata":"https://www.wikidata.org/wiki/Q194270","display_name":"Hallucinogen","level":2,"score":0.3712933361530304},{"id":"https://openalex.org/C542102704","wikidata":"https://www.wikidata.org/wiki/Q183257","display_name":"Psychotherapist","level":1,"score":0.3636138141155243}],"mesh":[{"descriptor_ui":"D001007","descriptor_name":"Anxiety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006213","descriptor_name":"Hallucinogens","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006213","descriptor_name":"Hallucinogens","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011562","descriptor_name":"Psilocybin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019966","descriptor_name":"Substance-Related Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.neuropharm.2023.109610","doi":"https://doi.org/10.1016/j.neuropharm.2023.109610","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.neuropharm.2023.109610","pdf_url":null,"source":{"id":"https://openalex.org/S160566677","display_name":"Neuropharmacology","issn_l":"0028-3908","issn":["0028-3908","1873-7064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"journal-article"},{"id":"pmid:37247807","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37247807","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"Editorial"}],"best_oa_location":{"id":"doi:10.1016/j.neuropharm.2023.109610","doi":"https://doi.org/10.1016/j.neuropharm.2023.109610","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.neuropharm.2023.109610","pdf_url":null,"source":{"id":"https://openalex.org/S160566677","display_name":"Neuropharmacology","issn_l":"0028-3908","issn":["0028-3908","1873-7064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W4280579129","https://openalex.org/W4282962482","https://openalex.org/W4283075222","https://openalex.org/W4283584241","https://openalex.org/W4291227674","https://openalex.org/W4292136326","https://openalex.org/W4293282462","https://openalex.org/W4297373842","https://openalex.org/W4306169038","https://openalex.org/W4308294035","https://openalex.org/W4310170729","https://openalex.org/W4311766514","https://openalex.org/W4312058527","https://openalex.org/W4313251651","https://openalex.org/W4317677634","https://openalex.org/W4322505390","https://openalex.org/W4324045013","https://openalex.org/W4362508370"],"related_works":["https://openalex.org/W3135459718","https://openalex.org/W4393098943","https://openalex.org/W2985843276","https://openalex.org/W2918650357","https://openalex.org/W4390270927","https://openalex.org/W4400574416","https://openalex.org/W4408107853","https://openalex.org/W4414440106","https://openalex.org/W4377081798","https://openalex.org/W4415932492"],"abstract_inverted_index":{"This":[0],"Special":[1,19],"Issue":[2,20],"of":[3,60,93,116,162,179,203,217,232],"Neuropharmacology":[4,18],"on":[5,13,36,48,53],"psychedelics":[6,37,218],"provides":[7],"a":[8,105],"timely":[9],"and":[10,33,86,88,100,128,147,183,185,193,200,212,240],"comprehensive":[11],"update":[12],"progress":[14,173],"following":[15],"the":[16,39,49,57,69,117,123,160,176],"previous":[17],"\"Psychedelics:":[21],"New":[22],"Doors,":[23],"Altered":[24],"Perceptions\".":[25],"Remarkable":[26],"advances":[27],"have":[28],"been":[29],"made":[30],"in":[31,38,122,140,145,152,167,172,181,186],"basic":[32,211],"clinical":[34,84],"research":[35],"five":[40],"years":[41],"since":[42],"2018.":[43],"It":[44],"is":[45],"partly":[46],"based":[47],"seminar":[50],"series":[51],"focused":[52],"psilocybin":[54,139,180],"organized":[55],"by":[56,114],"National":[58],"Institutes":[59],"Health":[61],"(NIH),":[62],"USA":[63],"from":[64,90,219],"April":[65],"to":[66,174,221],"June":[67],"2021,":[68],"\"NIH":[70],"Psilocybin":[71],"Research":[72],"Speaker":[73],"Series\".":[74],"Participants":[75],"were":[76],"world":[77],"leading":[78],"experts,":[79],"including":[80],"scientists,":[81],"medical":[82],"practitioners,":[83],"psychologists":[85],"oncologists,":[87],"attendees":[89],"additional":[91],"disciplines":[92],"patient":[94],"advocacy,":[95],"law,":[96],"government":[97],"science":[98,214],"policy":[99],"regulatory":[101],"policy.":[102],"To":[103],"provide":[104],"global":[106],"perspective,":[107],"their":[108],"contributions":[109],"are":[110,171,227],"complemented":[111],"with":[112],"reviews":[113],"some":[115],"world's":[118],"most":[119],"eminent":[120],"scientists":[121],"field.":[124],"The":[125,206,225],"US":[126],"Food":[127],"Drug":[129],"Administration":[130],"(FDA)":[131],"has":[132],"granted":[133],"two":[134],"breakthrough":[135],"therapy":[136],"designations":[137],"for":[138,157,159,215],"treatment":[141,161],"resistant":[142],"depression":[143],"(TRD)":[144],"2018":[146],"major":[148],"depressive":[149],"disorder":[150,165],"(MDD)":[151],"2019,":[153],"as":[154,156,190],"well":[155],"MDMA":[158],"post-traumatic":[163],"stress":[164],"(PTSD)":[166],"2017.":[168],"Clinical":[169],"trials":[170],"assess":[175],"therapeutic":[177],"value":[178],"MDD":[182],"TRD,":[184],"other":[187],"indications":[188],"such":[189],"cancer-related":[191],"anxiety":[192],"depression,":[194],"anorexia,":[195],"PTSD,":[196],"substance":[197],"use":[198],"disorders":[199],"various":[201],"types":[202],"chronic":[204],"pain.":[205],"contributors'":[207],"insights":[208],"should":[209],"assist":[210],"applied":[213],"transition":[216],"bench":[220],"potential":[222],"mainstream":[223],"therapies.":[224],"implications":[226],"global,":[228],"because":[229],"FDA":[230],"approval":[231],"these":[233],"new":[234],"medicines":[235],"will":[236],"increase":[237],"international":[238],"interest":[239],"efforts.":[241]},"counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":24},{"year":2024,"cited_by_count":18},{"year":2023,"cited_by_count":6}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2023-05-28T00:00:00"}